WO2024252366 - GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
National phase entry is expected:
Publication Number
WO/2024/252366
Publication Date
12.12.2024
International Application No.
PCT/IB2024/055618
International Filing Date
07.06.2024
Title **
[English]
GLP-1/GIP DUAL, GLP-1/GCG DUAL AND GLP-1/GIP/GCG TRIPLE RECEPTOR AGONISTS
[French]
AGONISTES DU RÉCEPTEUR DOUBLE GLP-1/GIP, DOUBLE GLP-1/GCG ET TRIPLE GLP-1/GIP/GCG
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
SUN HOUSE, PLOT NO. 201 B/1
WESTERN EXPRESS HIGHWAY, GOREGAON (E)
Mumbai 400063, IN
Inventors
THENNATI, Rajamannar
17A, 17B Pratham Avenue
Akota Road, Opp. Taj Vivanta, Akota
Vadodara 390020, IN
BURADE, Vinod Sampatrao
C-402, Kamalanjali Apt.
B/H Hdfc Bank, Akota Road, Akota
Vadodara 390020, IN
NATARAJAN, Muthukumaran
Villa No. 82, San Tropez, Madrid County,
Opposite to Ashapuri Mataji Mandir, Bhayli-Station Road, Bhayli
Vadodara 391410, IN
JOSHI, Dhiren Rameshchandra
203, Saundarya Greens-2
Canal Road, T.P. 13, Chhani Jakat Naka
Vadodara 390024, IN
GANDHI, Manish Harendraprasad
B-33 Devashish Duplex
Waghodia road Nr Manan park
Vadodara 390019, IN
JIVANI, Chandulal Thakarshiibhai
D-74 Balgopal Society
Nr Darbar chokadi, Manjalpur
Vadodara 390011, IN
TIWARI, Abhishek
1535-A, R. K. Puram
Sector A
Kota 324005, IN
SONI, Krunal Harishbhai
A-18, Palm Green Residency,
Ajwa-Waghodiya Ring Road
Vadodara 390019, IN
MARU, Alpeshbhai Balabhai
Juno gramya vistar,
Rupavati, Tal: Gariyadhar
Bhavnagar 364505, IN
DIXIT, Pankaj Vinodrao
R33, Near Radha Rani Appartment
Silicon City
Indore 452012, IN
PATELIYA, Bharatbhai Balabhai
C303, Shree Radhe Shyam,
Opp The Oakwood, Vasna Bhayli Road, Bhayli
Vadodara 391410, IN
NAGARAJA, Ravishankara Madavati
A-21, Nilamber Oriens
Opposite Shyamal Enclave, Sun Pharma Road, Tandalja
Vadodara 390012, IN
Priority Data
202321039646
09.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2047 | |
| EPO | Filing, Examination | 11897 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 14835 |
Total: 29948 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to GLP-1/GIP/GCG triple receptor agonists and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.[French]
La présente invention concerne des agonistes du récepteur triple GLP-1/GIP/GCG et leur utilisation dans le traitement ou la prévention du diabète sucré de type 2 (T2DM), de l'hyperlipidémie/dyslipidémie, de syndromes métaboliques, de la stéatose hépatique associée à un dysfonctionnement métabolique (MASLD), de la stéatohépatite associée à un dysfonctionnement métabolique (MASH), de troubles neurodégénératifs, de la fibrose, de risques cardiovasculaires et/ou de l'obésité.